The first study demonstrating good safety and clinical efficacy of a chemokine inhibitor in patients with RA evaluated eldelumab (MDX-1100), a fully human anti-CXCL10 (anti-IP-10) monoclonal antibody53; however, no further data were released. The gene discussed is CXCL10; the disease is rheumatoid arthritis.